University of Minnesota. Driven to Discover.
Milder infections aren't as hard to treat as multi-drug resistant ones and might be easier targets for new therapies.
Broad-spectrum antibiotics didn't produce better clinical or patient-centered results.
The FDA bans the marketing of OTC antiseptics containing triclosan and 23 other active antimicrobial agents.
A 3-track system would offer key advantages to the FDA's approach, the experts say.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.